The ANXA3 Knockout Jurkat Polyclonal Cells are a polyclonal CRISPR/Cas9-edited knockout cell population derived from the Jurkat T lymphoblastoid cell line, featuring targeted disruption of the ANXA3 gene. This loss-of-function model provides a defined genetic background to dissect ANXA3-dependent cellular processes, circumventing the limitations of transient knockdown approaches. The polyclonal nature of this product ensures representation of a range of knockout alleles, offering a robust population for functional studies without the bottleneck of single-cell cloning. Researchers can utilize these cells to explore the mechanistic roles of ANXA3 in signal transduction, membrane dynamics, and immune cell regulation.
The Jurkat cell line, originally established from a human acute T cell leukemia, is a well-characterized CD4+ T lymphocyte model extensively employed to investigate T cell receptor signaling, apoptosis, and cytokine responses. Its ease of manipulation and reproducible signaling characteristics make it an ideal chassis for gene-edited cell models. Jurkat cells express key components of the T cell activation machinery and faithfully recapitulate antigen receptor-induced pathways, including NF-??B and MAPK cascades, which are central to T cell biology and leukemogenesis. This host background enables direct examination of ANXA3 function within a physiologically relevant T cell context.
ANXA3 encodes a calcium-dependent phospholipid-binding protein that dynamically associates with membrane phospholipids and the actin cytoskeleton, influencing endocytosis, exocytosis, and membrane repair. At the molecular level, ANXA3 is positively regulated by pro-inflammatory stimuli such as TNF-?? and IL-6 via the JAK/STAT3 and NF-??B pathways. Once activated, ANXA3 engages multiple downstream effectors, including the PI3K/AKT and MAPK/ERK cascades, to promote cell proliferation and survival. Moreover, ANXA3 has been shown to enhance NF-??B transcriptional activity, leading to upregulation of matrix metalloproteinases (MMPs) and genes involved in cell migration. Key interacting partners include S100A6 and phospholipid components, which facilitate ANXA3-mediated membrane reorganization. Disruption of ANXA3 is therefore expected to impair signal transduction through these interconnected pathways, attenuating proliferative and migratory responses.
In the Jurkat T cell model, ANXA3 knockout allows for precise interrogation of its contributions to T cell activation and apoptosis. Jurkat cells rely on integrated signaling from surface receptors to cytoplasmic effectors; ANXA3 may modulate these signals by reorganizing membrane microdomains and scaffolding critical kinases such as AKT and MAPKs. Loss of ANXA3 could blunt NF-??B activation downstream of TCR stimulation, thereby altering cytokine production and apoptotic thresholds. This model is particularly valuable for dissecting how ANXA3 intersects with oncogenic pathways in T cell leukemia and for assessing its role in inflammatory signaling networks that drive immune cell dysfunction.
These polyclonal knockout cells are suitable for a wide range of functional assays, including western blotting and RT-qPCR to confirm gene disruption, flow cytometry for apoptosis and cell cycle profiling, and MTS/MTT-based proliferation assays. Phospho-specific flow cytometry and immunoblotting can be employed to evaluate ANXA3-dependent changes in AKT and NF-??B phosphorylation, while migration assays assess effects on cell motility. Co-immunoprecipitation studies with S100A6 or phospholipid-binding assays can further clarify ANXA3 molecular interactions. Additionally, drug sensitivity testing can be performed to explore ANXA3??s involvement in chemoresistance. These applications position the ANXA3 Knockout Jurkat Polyclonal Cells as a powerful tool for cancer biology, immunology, and drug discovery research. For additional technical specifications and ordering assistance, please contact Ascent Research.
